The identification of KIT and PDGFRA mutations fundamentally reshaped the biological classification and clinical management of GIST, distinguishing it from other sarcomas and enabling molecularly targeted therapeutic development [11,12,13]. Here, KIT is linked to gastrointestinal stromal tumor.